

August 4, 2021  
Symbio Pharmaceuticals Limited  
(Securities Code: 4582)  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer

## Notice Concerning Non-operating Expenses

Symbio Pharmaceuticals Limited (“the Company”) announces accrued non-operating expenses for the second quarter of the fiscal year ending December 31, 2021 (from April 1, 2021 to June 30, 2021).

### 1. Details of Non-operating Expenses

The Company recorded a foreign exchange loss of 9,304 thousand yen under non-operating expenses for the second quarter of the fiscal year ending December 31, 2021 (from April 1, 2021 to June 30, 2021) due to recent fluctuations in foreign exchange rates. In addition, with a foreign exchange loss of 8,687 thousand yen for the first quarter ended March 31, 2021, a total foreign exchange loss of 17,991 thousand yen was recorded as statements of operations for the first half of the fiscal year ending December 31, 2021.

### 2. Future Outlook

Based on its assumption concerning operational trends for this fiscal year, the Company determined that this non-operating expense would have no significant impact on the results of operations for the year with no modification to the financial forecast required. The Company will make a prompt announcement should any modification to the financial forecast be necessary.

### [Contact]

Investor Relations  
Tel: +81(0)3 5472 1125